- Prostate Cancer Overview
- Epidemiology of Prostate Cancer: St Lucia
- Role of Universal Health Coverage (UHC)
- Project Goal & Objectives
- Key Performance Indicators
- Prostate Cancer KPIs
- Review M&E Worksheet
2024-11-08
Prostate cancer ranks among the most prevalent cancers in men, with approximately 1.4 million new diagnoses worldwide in 2022.
It is the second most common cancer affecting the male population globally.
About 1 in 8 men will be diagnosed with prostate cancer in their lifetime.
Risk factors: older ages, African/Caribbean descent, obesity, diet
Source: American Cancer Society
Prostate cancer continues to have the highest incidence in St Lucia over the past 5 years (exception:2021)
Relaunch of Men’s health clinic under UHC to include prostate cancer screening
Prostate-Specific Antigen (PSA) tests will be offered at phlebotomy sites in wellness centers around the island along with Digital Rectal Exams (DRE)
Patients with abnormal PSA levels and/or DRE will be referred to the Urology Clinic for Transrectal Ultrasounds (TRUS)
KPIs were developed to assess the progress of UHC in meeting project goals for prostate cancer screening.
KPIs may not directly improve quality but they act as effective flags or alerts, that help pinpoint best practices, enable comparisons among similar services and highlight areas of improvement.
The primary objectives of KPIs are to:
Monitor progress
Identify areas for improvement
enhance accountability
ensure strategic alignment
Screening coverage
PSA test
DRE test
Co-testing rate
Elevated PSA Levels
Abnormal DRE rates
Patient Refusal Rate
Proportion of men with abnormal screen tests who require follow-up procedures
Number of patients seen by urologist within 21 days of referral
Proportion of men who received imaging tests
Biopsy referral rates
Positive biopsy rates
Clinically significant cases
Early-stage detection
Late-stage detection
Proportion of PSA test results available within 1 week of testing
Proportion of men informed of elevated PSA results 1 week (5 working days) after receiving results
Proportion of men informed of normal PSA results within 10 working days from receipt of results
Number of biopsy results available within 1 week of procedure
Number of men notified of biopsy results within 1 week (5 working days) of results being made available
Number of men treated within 4 weeks of diagnosis
Sample rejection rate
False Positive Rate
False Negative Rate
Gleason Scores (GS)
Prostate cancer treatment rate
Proportion of men placed in active surveillance